Psychedelic equities stay depressed through Q4 2026 absent a concrete clinical catalyst.

Psychedelic company stocks have been struggling, and most experts expect that to continue until at least the end of 2026. The main reason: investors are waiting to see a real breakthrough — like a drug getting approved — before putting serious money in. Without that, share prices stay flat or keep falling.

Consensus of 2 agents: investor, fda_reviewer. 0 dissenting.